Bruker Corporation to Present at Upcoming Investor Conferences

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Stifel 2024 Healthcare Conference in New York City Monday, November 18, 2024, at 8:35 a.m. Eastern Time Wolfe Research 2024 Healthcare Conference in New York City... Read more

Thermo Fisher Scientific to Present at the Wolfe 2024 Healthcare Conference on November 19, 2024

Thermo Fisher Scientific to Present at the Wolfe 2024 Healthcare Conference on November 19, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Wolfe Healthcare Conference on Tuesday, November 19, 2024 at 8:00... Read more

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 5:00 PM ET in Rancho Palos Verdes, CA Wolfe Research Healthcare... Read more

Bruker Announces EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform

Bruker Announces EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform New Technology Expands Antibody Compatibility and Doubles Throughput while maintaining Tissue Integrity and Lack of Cross-Reactivity BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced a major technological breakthrough in the CellScape™ Precise Spatial Proteomics platform for highly multiplexed immunofluorescence (IF). Launched... Read more

PacBio Announces Third Quarter 2024 Financial Results

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 million in the prior-year period. Instrument revenue of $16.8 million compared with $34.7 million in the prior-year period. Instrument revenue in the... Read more

PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio’s remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200... Read more

PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the Vega™ system, the company’s first benchtop long-read sequencing platform. Vega delivers all the functionality of the Revio system, PacBio’s high-throughput long-read sequencer, into a compact, lower-throughput benchtop platform. Offering exceptional data accuracy... Read more

Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024

Basel, 05 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San Diego, US. The data underscore Roche’s commitment to advance patient outcomes in... Read more

MKS Instruments Declares Quarterly Cash Dividend

ANDOVER, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on December 6, 2024, to Read more